The peroxisome, an ubiquitous subcellular organelle, plays an important function in cellular metabolism, and its importance for human health is underscored by the identification of fatal disorders caused by genetic abnormalities. Recent findings indicate that peroxisomal dysfunction is not only restricted to inherited peroxisomal diseases but also to disease processes associated with generation of inflammatory mediators that downregulate cellular peroxisomal homeostasis. Evidence indicates that leukodystrophies (i.e. X-linked adrenoleukodystrophy, globoid cell leukodystrophy, and periventricular leukomalacia) may share common denominators in the development and progression of the inflammatory process and thus in the dysfunctions of peroxisomes. Dysfunctions of peroxisomes may therefore contribute in part to white matter disease and to the mental and physical disabilities that develop in patients affected by these diseases.
Schrader M., Fahimi HDPeroxisomes and oxidative stress. Biochim Biophys Acta. 2006;1763(12):1755-1766.
5.
Baudhuin P., Beaufay H., Rahman-Li Y., et al. Tissue fractionation studies. 17. Intracellular distribution of monoamine oxidase, aspartate aminotransferase, alanine aminotransferase, D-amino acid oxidase and catalase in rat-liver tissue. Biochem J. 1964; 92(1):179-184.
6.
Boveris A., Oshino N., Chance B.The cellular production of hydrogen peroxide. Biochem J. 1972;128(3):617-630.
7.
Singh I., Voigt RG, Sheikh FG, Kremser K., Brown FR 3rd.Biochemical features of a patient with Zellweger-like syndrome with normal PTS-1 and PTS-2 peroxisomal protein import systems: a new peroxisomal disease . Biochem Mol Med.1997;61(2):198-207.
8.
Contreras M., Singh I.Adrenoleukodystrophy: molecular, metabolic, pathologic, and therapeutic aspects . In: Lajtha A, ed. Handbook of Neurochemistry and Molecular Neurobiology. New York : Springer; 2009:13-42.
9.
Moser HW, Smith KD, Watkins PA, Powers J., Moser ABX-linked adrenoleukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. New York: McGraw-Hill;2001:3257-3301.
10.
Gould SJ, Raymond GV, Valle D.The peroxisome biogenesis disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill ; 2001:3181-3217.
11.
Wanders RJ, Barth PG, Heymans HSSingle peroxisomal enzyme deficiencies. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. New York: McGraw-Hill;2001:3219-3256.
12.
Lazo O., Singh AK, Singh I.Postnatal development and isolation of peroxisomes from brain. J Neurochem. 1991;56(4): 1343-1353.
13.
Kassmann CM , Lappe-Siefke C., Baes M., et al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet.2007;39(8):969-976.
14.
Krysko O., Hulshagen L., Janssen A., et al. Neocortical and cerebellar developmental abnormalities in conditions of selective elimination of peroxisomes from brain or from liver. J Neurosci Res. 2007;85(1):58-72.
15.
Contreras M. , Mosser J., Mandel JL, Aubourg P., Singh I.The protein coded by the X-adrenoleukodystrophy gene is a peroxisomal integral membrane protein. FEBS Lett . 1994; 344(2-3):211-215.
Lazo O., Contreras M., Hashmi M., Stanley W., Irazu C., Singh I.Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci U S A. 1988;85(20):7647-7651.
18.
Tsuji S., Sano T., Ariga T., Miyatake T.Increased synthesis of hexacosanoic acid (C23:0) by cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN) . J Biochem. 1981;90(4):1233-1236.
19.
Maestri NE, Beaty THPredictions of a 2-locus model for disease heterogeneity: application to adrenoleukodystrophy . Am J Med Genet. 1992;44(5):576-582.
20.
Moser HW, Moser AB, Smith KD, et al. Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis. 1992;15(4):645-664.
21.
Lombard-Platet G., Savary S., Sarde CO, Mandel JL, Chimini G.A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern . Proc Natl Acad Sci U S A.1996;93(3):1265-1269.
22.
Kamijo K., Taketani S., Yokota S., Osumi T., Hashimoto T.The 70-kDa peroxisomal membrane protein is a member of the Mdr (P-glycoprotein)-related ATP-binding protein superfamily. J Biol Chem. 1990;265(8):4534-4540.
23.
Shani N., Jimenez-Sanchez G., Steel G., Dean M., Valle D.Identification of a fourth half ABC transporter in the human peroxisomal membrane . Hum Mol Genet. 1997;6(11): 1925-1931.
24.
Kemp S., Wei HM, Lu JF, et al. Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med. 1998;4(11):1261-1268.
25.
Gondcaille C., Depreter M., Fourcade S., et al. Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J Cell Biol . 2005;169(1): 93-104.
26.
Pujol A., Ferrer I., Camps C., et al. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet . 2004; 13(23):2997-3006.
27.
Berger J., Albet S., Bentejac M., et al. The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. Eur J Biochem. 1999;265(2): 719-727.
28.
Troffer-Charlier N., Doerflinger N., Metzger E., Fouquet F., Mandel JL, Aubourg P.Mirror expression of adrenoleukodystrophy and adrenoleukodystrophy related genes in mouse tissues and human cell lines . Eur J Cell Biol. 1998;75(3):254-264.
29.
Maier EM, Mayerhofer PU, Asheuer M., et al. X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype. Biochem Biophys Res Commun. 2008 ;377(1):176-180.
30.
Hein S., Schonfeld P., Kahlert S., Reiser G.Toxic effects of Xlinked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Hum Mol Genet. 2008;17(12):1750-1761.
31.
Paintlia AS , Gilg AG, Khan M., Singh AK, Barbosa E., Singh I.Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol Dis. 2003 ; 14(3):425-439.
32.
Khan M., Pahan K., Singh AK, Singh I.Cytokine-induced accumulation of very long-chain fatty acids in rat C6 glial cells: implication for X-adrenoleukodystrophy. J Neurochem . 1998; 71(1):78-87.
33.
Khan M., Singh J., Singh I.Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J Neurochem. 2008;106(4):1766-1779.
34.
Lu JF, Lawler AM, Watkins PA, et al. A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A. 1997;94(17):9366-9371.
35.
Singh J., Khan M., Singh I.Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. J Lipid Res. 2009;50(1):135-147.
36.
Di Benedetto R., Denti MA, Salvati S., Attorri L., Di Biase A.PMP70 knock-down generates oxidative stress and pro-inflammatory cytokine production in C6 glial cells. Neurochem Int. 2009;54(1):37-42.
37.
Di Biase A. , Merendino N., Avellino C., Cappa M., Salvati S.Th 1 cytokine production by peripheral blood mononuclear cells in X-linked adrenoleukodystrophy. J Neurol Sci. 2001;182(2): 161-165.
38.
Lannuzel A. , Aubourg P., Tardieu M.Excessive production of tumour necrosis factor alpha by peripheral blood mononuclear cells in X-linked adrenoleukodystrophy . Eur J Paediatr Neurol. 1998;2(1):27-32.
39.
Powers JM, Pei Z., Heinzer AK, et al. Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol. 2005;64(12):1067-1079.
40.
Fourcade S., Lopez-Erauskin J., Galino J., et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy . Hum Mol Genet. 2008;17(12):1762-1773.
41.
Pujol A., Hindelang C., Callizot N., Bartsch U., Schachner M., Mandel JLLate onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet. 2002;11(5):499-505.
42.
Haq E., Contreras MA, Giri S., Singh I., Singh AKDysfunction of peroxisomes in twitcher mice brain: a possible mechanism of psychosine-induced disease. Biochem Biophys Res Commun. 2006;343(1):229-238.
43.
Khan M., Haq E., Giri S., Singh I., Singh AKPeroxisomal participation in psychosine-mediated toxicity: Implications for Krabbe’s disease. J Neurosci Res. 2005 ;80(6):845-854.
44.
Wenger DA, Suzuki K., Suzuki Y., Suzuki K.Galactosylceramide lipidosis: Globoid cell leukodystrophy (Krabbe Disease) . In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. New York: McGraw-Hill;2001:3669-3694.
45.
Igisu H., Suzuki K.Progressive accumulation of toxic metabolite in a genetic leukodystrophy. Science. 1984; 224(4650):753-755.
46.
Contreras MA , Haq E., Uto T., Singh I., Singh AKPsychosine-induced alterations in peroxisomes of twitcher mouse liver. Arch Biochem Biophys. 2008; 477(2):211-218.
47.
Suzuki K., Suzuki K.The twitcher mouse. A model of human globoid cell leukodystrophy (Krabbe’s disease). Am J Pathol. 1983;111(3):394-397.
48.
LeVine SM, Brown DCIL-6 and TNFalpha expression in brains of twitcher, quaking and normal mice. J Neuroimmunol. 1997; 73(1-2):47-56.
49.
Giri S., Jatana M., Rattan R., et al. Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease. FASEB J. 2002;16(7):661-672.
50.
Haq E., Giri S., Singh I., Singh AKMolecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line. J Neurochem. 2003;86(6):1428-1440.
51.
Taniike M., Mohri I., Eguchi N., et al. An apoptotic depletion of oligodendrocytes in the twitcher, a murine model of globoid cell leukodystrophy. J Neuropathol Exp Neurol. 1999;58(6): 644-653.
52.
Itoh M., Hayashi M., Fujioka Y., Nagashima K., Morimatsu Y., Matsuyama H.Immunohistological study of globoid cell leukodystrophy. Brain Dev. 2002;24(5):284-290.
53.
Ohno M., Komiyama A., Martin PM, Suzuki K.MHC class II antigen expression and T-cell infiltration in the demyelinating CNS and PNS of the twitcher mouse. Brain Res. 1993;625(2): 186-196.
54.
Yasmineh WG , Parkin JL, Caspers JI, Theologides A.Tumor necrosis factor/cachectin decreases catalase activity of rat liver. Cancer Res. 1991;51(15):3990-3995.
55.
Singh I., Paintlia AS, Khan M., et al. Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Res. 2004;1022(1-2): 1-11.
56.
Dobashi K., Pahan K., Chahal A., Singh I.Modulation of endogenous antioxidant enzymes by nitric oxide in rat C6 glial cells. J Neurochem. 1997;68(5):1896-1903.
57.
Keng T., Privalle CT, Gilkeson GS, Weinberg JBPeroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice. Mol Med. 2000;6(9):779-792.
58.
Beier K., Volkl A., Fahimi HDSuppression of peroxisomal lipid beta-oxidation enzymes of TNF-alpha. FEBS Lett. 1992; 310(3): 273-276.
59.
Contreras MA , Khan M., Smith BT, et al. Endotoxin induces structure-function alterations of rat liver peroxisomes: Kupffer cells released factors as possible modulators. Hepatology. 2000;31(2):446-455.
60.
Beier K., Volkl A., Fahimi HDTNF-alpha downregulates the peroxisome proliferator activated receptor-alpha and the mRNAs encoding peroxisomal proteins in rat liver. FEBS Lett. 1997;412(2):385-387.
61.
Delerive P. , Fruchart JC, Staels B.Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001 ;169(3):453-459.
62.
Khwaja O., Volpe JJPathogenesis of cerebral white matter injury of prematurity. Arch Dis Child Fetal Neonatal Ed. 2008; 93(2):F153-F161.
63.
Deng W., Pleasure J., Pleasure D.Progress in periventricular leukomalacia. Arch Neurol. 2008;65(10):1291-1295.
64.
Pang Y., Cai Z., Rhodes PGEffects of lipopolysaccharide on oligodendrocyte progenitor cells are mediated by astrocytes and microglia. J Neurosci Res. 2000;62(4):510-520.
65.
Bell MJ, Hallenbeck JMEffects of intrauterine inflammation on developing rat brain. J Neurosci Res. 2002;70(4):570-579.
66.
Deng W., Wang H., Rosenberg PA, Volpe JJ, Jensen FERole of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress. Proc Natl Acad Sci U S A. 2004; 101(20):7751-7756.
67.
Haynes RL, Folkerth RD, Keefe RJ, et al. Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. J Neuropathol Exp Neurol . 2003;62(5): 441-450.
68.
Li J., Ramenaden ER, Peng J., et al. Tumor necrosis factor alpha mediates lipopolysaccharide-induced microglial toxicity to developing oligodendrocytes when astrocytes are present . J Neurosci. 2008;28(20):5321-5330.
69.
Paintlia MK , Paintlia AS, Barbosa E., Singh I., Singh AKN-acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. J Neurosci Res. 2004;78(3):347-361.
70.
Paintlia MK , Paintlia AS, Contreras MA, Singh I., Singh AKLipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: attenuation by N-acetyl cysteine . Exp Neurol. 2008;210(2):560-576.
71.
Issemann I. , Green S.Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347(6294):645-650.
72.
Paintlia MK , Paintlia AS, Khan M., Singh I., Singh AKModulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures. J Neurochem. 2008;105(3):956-970.
